Mega Lifesciences PCL
SET:MEGA
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (9), the stock would be worth ฿38.67 (15% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 7.9 | ฿33.75 |
0%
|
| 3-Year Average | 9 | ฿38.67 |
+15%
|
| 5-Year Average | 11.1 | ฿47.57 |
+41%
|
| Industry Average | 8.3 | ฿35.44 |
+5%
|
| Country Average | 8.6 | ฿36.99 |
+10%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
฿26.5B
|
/ |
Jan 2026
฿3.2B
|
= |
|
|
฿26.5B
|
/ |
Dec 2026
฿3.4B
|
= |
|
|
฿26.5B
|
/ |
Dec 2027
฿3.7B
|
= |
|
|
฿26.5B
|
/ |
Dec 2028
฿3.7B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| TH |
M
|
Mega Lifesciences PCL
SET:MEGA
|
29.4B THB | 7.9 | 15.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
879B USD | 28.7 | 42.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
576.7B USD | 14.9 | 21.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
256.6B CHF | 11.8 | 19.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
233.8B CHF | 13.3 | 21.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
222.9B GBP | 16.2 | 29.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
286.7B USD | 9.7 | 15.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 344.9 | -74.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 8.1 | 11 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.3B USD | 7.7 | 20.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121.9B USD | 7.2 | 17.1 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 6.6 |
| Median | 8.6 |
| 70th Percentile | 11.4 |
| Max | 3 584.8 |
Other Multiples
Mega Lifesciences PCL
Glance View
Mega Lifesciences Public Co. Ltd. engages in the manufacture, market, sale, and distribution of pharmaceutical, nutraceutical products, and consumer goods. The company is headquartered in Bangkok, Bangkok Metropolis. The company went IPO on 2013-11-19. The firm's products include complimentary medicines, over-the-counter (OTC) medicines and prescription medicines to both domestic and international markets. The company distributes products under Maxxcare brand covering prescription pharmaceutical products, OTC drugs and other consumer products. The firm also offers nutritional products, prescription pharmaceutical products and OTC drugs under Mega We Care brand. In addition, the Company operates as an original equipment manufacturer (OEM) for various products including health supplements, pharmaceutical, herbal products, vitamins and minerals, among others.
